-
Ionophore Toxicity Mechanisms and Tiamulin Interactions in A
2026-05-14
This review explores ionophore toxicity in animals, emphasizing clinical and molecular mechanisms that underlie adverse effects, particularly in veterinary contexts. It highlights the crucial role of Tiamulin-ionophore interactions and the implications for safer antibiotic and coccidiostat use in animal health.
-
Gut-Brain Cholinergic Signaling and Seizure Control via B. f
2026-05-14
Jia et al. establish that Bacteroides fragilis suppresses seizures by enhancing gut-brain cholinergic signaling through activation of colonic ChAT+ cells and vagal pathways. Their multidisciplinary approach reveals a mechanistic link between microbiota composition and neural circuitry, with implications for microbiota-targeted therapies in pediatric refractory epilepsy.
-
Shufeng Xingbi Therapy Modulates Th1/Th2 Balance and Gut Flo
2026-05-13
This study systematically investigates how Shufeng Xingbi Therapy (SFXBT) impacts immune regulation and gut microbiota in a rat model of allergic rhinitis. The findings reveal that SFXBT restores Th1/Th2 immune balance, reduces inflammation, and beneficially remodels the intestinal flora—offering mechanistic insights with translational relevance for immune-microbiota research.
-
5-HT3 Antagonists Inhibit Renal OCT2/MATE1: Mechanistic Insi
2026-05-13
This study systematically demonstrates that antiemetic 5-HT3 receptor antagonists, including tropisetron, inhibit the renal cation transporters OCT2 and MATE1 in vitro, thereby altering the secretion of cationic drugs. These findings have important implications for drug-drug interactions and the pharmacokinetic behavior of compounds eliminated via renal secretion.
-
WNT5a/GSK3/β-catenin Axis Governs FAP Adipogenesis in Muscle
2026-05-12
This study delineates how the WNT5a/GSK3/β-catenin pathway regulates the adipogenic fate of skeletal muscle fibro/adipogenic progenitors (FAPs). By utilizing integrated pharmacological, cytometric, and transcriptomic approaches, the researchers reveal modulation of this axis as a promising strategy to restrict fat infiltration and promote muscle regeneration in myopathies.
-
PP2A-Mediated Autophagy Drives Drug Resistance in C. albican
2026-05-12
This study uncovers a mechanistic link between protein phosphatase 2A (PP2A)-mediated autophagy and drug resistance in Candida albicans biofilms. The findings offer new insights for antifungal strategies targeting autophagy regulation, with implications for overcoming clinical drug resistance.
-
BET Bromodomain Inhibitor (+)-JQ1: Mechanistic Insights and
2026-05-11
Explore the advanced molecular mechanisms and translational applications of Bromodomain Inhibitor, (+)-JQ1, a potent BET bromodomain inhibitor. This article delivers in-depth analysis, unique reference integration, and actionable guidance for apoptosis assay design, inflammation modulation, and male contraception research.
-
Cyclosporin A in Research: Optimized Workflows and Troublesh
2026-05-11
Cyclosporin A is indispensable for dissecting immune suppression, apoptosis, and viral mechanisms in both cell and animal models. This article translates cutting-edge findings and real-world lab workflows into actionable protocols, offering troubleshooting guidance and advanced application insights for maximizing experimental reliability.
-
ER-Targeted EISA Peptides Drive Selective Cancer Cell Death
2026-05-10
This study introduces a peptide platform that leverages enzyme-instructed self-assembly (EISA) to target the endoplasmic reticulum (ER) in cancer cells, using alkaline phosphatase (ALP) overexpression for precise cytotoxicity. The approach enhances efficacy and selectivity in modulating cancer cell fate, offering a significant advance over previous organelle-targeted strategies.
-
Biotin-16-UTP: Precision Biotin-Labeled RNA for Advanced Ass
2026-05-09
Biotin-16-UTP empowers researchers with robust, high-sensitivity RNA labeling for detection, purification, and interactome mapping. Its versatility and workflow compatibility make it the reagent of choice for dissecting lncRNA function, as proven in recent hepatocellular carcinoma studies.
-
KR-12 Peptide Mitigates Colitis Inflammation and Bacterial B
2026-05-08
This study establishes KR-12, the smallest active fragment of human cathelicidin LL-37, as an effective agent for reducing inflammation and bacterial load in mouse models of colitis. The findings highlight KR-12’s dual anti-inflammatory and antibacterial effects, supporting its relevance for inflammatory bowel disease research.
-
Ibrexafungerp Activity Against Echinocandin-Resistant Candid
2026-05-08
This study systematically evaluates ibrexafungerp's in vitro efficacy against a large collection of echinocandin-resistant Candida isolates, focusing on the impact of specific FKS mutations. The findings highlight differential susceptibility patterns, with ibrexafungerp retaining notable activity in certain resistant phenotypes, informing antifungal strategy development.
-
Flumequine (SKU B2292): Precision DNA Topoisomerase II Inhib
2026-05-07
This article explores how Flumequine (SKU B2292), a rigorously characterized DNA topoisomerase II inhibitor, enhances assay reproducibility and sensitivity for cell viability, proliferation, and cytotoxicity studies. Drawing on scenario-driven Q&A and literature-backed insights, we demonstrate how Flumequine addresses core experimental challenges, supporting reliable results across cancer and DNA replication research workflows.
-
WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc
2026-05-07
This study identifies the canonical WNT5a/GSK3/β-catenin pathway as a critical regulator of adipogenic differentiation in muscle-resident fibro/adipogenic progenitors (FAPs). By integrating pharmacological inhibition, single-cell analysis, and in vivo models, the authors reveal new therapeutic targets for limiting fatty degeneration in muscle diseases and highlight the complexity of intercellular signaling in tissue homeostasis.
-
Structural Basis of TRPM3 Regulation by Neurosteroids and An
2026-05-06
Yin et al. elucidate the molecular mechanisms by which neurosteroids and the anticonvulsant primidone modulate TRPM3 ion channel activity, leveraging cryo-EM to locate ligand binding sites and characterize disease-associated mutations. Their findings offer foundational insights relevant to both pain and neurodevelopmental disorder therapeutics.